This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Bermekimab
- DrugBank Accession Number
- DB14947
- Background
Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Bermekimab
- RA-18C3
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Bermekimab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bermekimab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Bermekimab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bermekimab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Bermekimab. Ambroxol The risk or severity of methemoglobinemia can be increased when Bermekimab is combined with Ambroxol. Amivantamab The risk or severity of adverse effects can be increased when Bermekimab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Bermekimab. Ansuvimab The risk or severity of adverse effects can be increased when Bermekimab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Bermekimab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- L01FX11 — Bermekimab
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N6SVN735GY
- CAS number
- 1401965-15-8
References
- General References
- Not Available
- External Links
- Wikipedia
- Bermekimab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Acne Inversa / Hidradenitis Suppurativa (HS) / Suppurative Hidradenitis 1 2 Completed Treatment Acne Vulgaris 1 2 Completed Treatment Atopic Dermatitis 2 2 Completed Treatment Hidradenitis Suppurativa (HS) 1 2 Completed Treatment Psoriasis 1 2 Completed Treatment Scleroderma, Systemic 1 2 Terminated Treatment Atopic Dermatitis 2 2 Terminated Treatment Hidradenitis Suppurativa (HS) 1 1 Completed Other Healthy Subjects (HS) 2 1 Withdrawn Other Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:37 / Updated at February 21, 2021 18:55